NORTHERN-DATA-AG
21.7.2020 07:34:11 CEST | Business Wire | Press release
Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87 ), one of the world's largest providers of high-performance-computing (HPC) solutions, has developed proprietary HPC services in cooperation with the leading Taiwanese computer hardware manufacturer Gigabyte Technology (Taiwan Stock Exchange: 2376, ISIN: TW0002376001 ).
Northern Data's partnership with Gigabyte covers the production, supply and combination of components, where Northern Data tests specific processors (GPUs, CPUs, etc.) and selects them for the respective applications and Gigabyte combines these processors with its specialised server architecture. In doing so, Gigabyte adjusts the GPU clusters developed by Northern Data to meet all of Northern Data's technical requirements. A GPU cluster is a computer network in which each node (processing unit) is equipped with several Graphic Processing Units (GPU). The high-density GPU clusters used in these processes are specially designed for high-performance-computing (HPC) applications.
The server architecture created on this basis is the foundation for so-called distributed computing. Distributed computing involves running software across multiple computer systems working in parallel, in order to increase their efficiency, reliability and performance. With these new, tailor-made high-density GPU clusters, Northern Data can meet the highly specific requirements of their customers, providing them with the required computing power for their respective HPC applications as easily and efficiently as possible. This service will then be used in Northern Data's data centers for individually developed customer solutions.
GPU-based, parallel processing of data enables highly complex, computationally intensive HPC applications to be executed efficiently, reliably and quickly, particularly in the domains of artificial intelligence and rendering.
This combination of Gigabyte's expertise in manufacturing HPC hardware and Northern Data's experience in managing and orchestrating large-scale facilities (with proprietary AI software and its own thermal management system) opens up new opportunities for Northern Data customers to scale their operations even further than before. Northern Data distinguishes itself from other providers by the composition and combination of hardware and software, the way it is made available and, above all, by the favourable pricing for customers.
"The demand for HPC is booming; the rendering and AI sectors are enormous growth markets. We are pleased to have Gigabyte Technologies, one of the leading suppliers in the young HPC sector, on board as our development partner, and we are now excited to announce this business partnership," explains Aroosh Thillainathan, CEO of Northern Data AG, and continues: "We have already worked together on various GPU-based HPC projects, as we believe that Gigabyte's servers are among the best hardware for HPC in the world. Hence, we are very pleased to deepen our partnership with a manufacturer with this level of expertise and to have them accompany our R&D process. Gigabyte is the right strategic partner to help us make the concept of distributed computing a reality for many HPC applications".
Northern Data CFO Mathis Schultz adds: "So far, our customers are predominantly in the bitcoin mining sector, which was the first mass-scale HPC application. But the demand from other sectors is growing rapidly, accelerated in part by the Covid-19 crisis. The partnership with Gigabyte Technologies allows us to build out our market-leading position with bitcoin mining clients, into new sectors."
And Thomas Yen, European head of Gigabyte Technologies explains: "We are pleased to now officially announce our partnership with Northern Data. We see great potential in our jointly-designed GPU clusters. We are excited to work closely with Northern Data as a strategic partner and high-potential customer in the field of HPC."
About Northern Data:
Northern Data AG builds and offers global infrastructure solutions in the field of high-performance computing (HPC), offering solutions in the fields of machine learning and artificial intelligence, big data analytics, blockchain applications, game streaming and more. Operating internationally the company evolved from the merger of German Northern Bitcoin AG and American Whinstone US, Inc. and is now a recognized leader in the provision of HPC solutions worldwide. The company offers HPC solutions, both stationary in large state-of-the-art data centers as well as in high-tech mobile data centers, which can be deployed in any location worldwide. In doing so, it combines self-developed software and hardware with novel concepts to ensure a sustainable and reliable energy supply. In Texas, Northern Data is running the USA's largest HPC data center and, at the same time, the world's largest dedicated HPC facility. Further information can be found at www.northerndata.de .
About Gigabyte Technology Co., Ltd.
Gigabyte Technology Co., Ltd. is a Taiwan-based company principally engaged in the production, processing and sales of information technology (IT) products. The company provides computer motherboards, three dimensional (3D) display graphic cards, laptops, tablets, personal computers (PCs), servers, smart phones, broadband network devices and wireless communication products, computer peripherals and network storage products. It distributes its products mainly within Taiwan, as well as to the rest of Asia, Europe and the Americas.
Disclaimer:
This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities of Northern Data AG and does not constitute a prospectus of Northern Data AG. The information contained in this press release is not intended to form the basis of any financial, legal, tax or other business decision. Investment or other decisions should not be made solely on the basis of this press release. As with all business and investment matters, please consult qualified professional advice.
| Language: | English |
| Company: | Northern Data AG |
| Thurn-und-Taxis-Platz 6 | |
| 60313 Frankfurt/Main | |
| Germany | |
| Phone: | +49 69 34 87 52 25 |
| E-mail: | info@northerndata.de |
| Internet: | www.northerndata.de |
| ISIN: | DE000A0SMU87 |
| WKN: | A0SMU8 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich (m:access), Tradegate Exchange |
| EQS News ID: | 1097883 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200720005840/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
